Brief Report: Real-World Uptake and Clinical Outcomes of Long-Acting Injectable Cabotegravir/Rilpivirine in the United States, 2021-2023.
- DOI
- 10.1097/qai.0000000000003855
- Published
- 2026 Jul 1
- Container
- Journal of acquired immune deficiency syndromes (1999)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1097/qai.0000000000003855,
title = {Brief Report: Real-World Uptake and Clinical Outcomes of Long-Acting Injectable Cabotegravir/Rilpivirine in the United States, 2021-2023.},
author = {O'Shea J and Derton A and Henson J and Iqbal K and Briggs-Hagen M and Kourtis AP and Buchacz K},
year = {2026},
journal = {Journal of acquired immune deficiency syndromes (1999)},
doi = {10.1097/qai.0000000000003855},
url = {https://doi.org/10.1097/qai.0000000000003855}
}RIS
TY - JOUR TI - Brief Report: Real-World Uptake and Clinical Outcomes of Long-Acting Injectable Cabotegravir/Rilpivirine in the United States, 2021-2023. AU - O'Shea J AU - Derton A AU - Henson J AU - Iqbal K AU - Briggs-Hagen M AU - Kourtis AP AU - Buchacz K PY - 2026 JO - Journal of acquired immune deficiency syndromes (1999) DO - 10.1097/qai.0000000000003855 UR - https://doi.org/10.1097/qai.0000000000003855 ER -
APA
J, O., A, D., J, H., K, I., M, B., AP, K., & K, B. (2026). Brief Report: Real-World Uptake and Clinical Outcomes of Long-Acting Injectable Cabotegravir/Rilpivirine in the United States, 2021-2023.. Journal of acquired immune deficiency syndromes (1999). https://doi.org/10.1097/qai.0000000000003855
Source records
- pubmed · retrieved 2026-09-26T10:22:57.350Z